Spy072

Phase 2

SSpyre Therapeutics, Inc.

Spy072 is one of 8 therapeutic programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hidradenitis Suppurativa (HS)Not yet recruiting

Hidradenitis Suppurativa (HS)Phase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Hidradenitis Suppurativa (HS)

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Approved

1 2

Povorcitinib

Incyte

Phase 3

3 3

Bimzelx

UCB

Phase 2

1 4

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 5

Tibulizumab

ZZura Bio Inc

Phase 2

1 6

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 1

1 7

Spy072

SSpyre Therapeutics, Inc.

Phase 2

1 8

NAV-240

NNavigator Medicines, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Hidradenitis Suppurativa (HS)

NCT07766005

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment

Not yet recruiting·SSpyre Therapeutics, Inc.·Phase 2·NCT07766005·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spy072. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Spy072. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Spyre Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSpyre Therapeutics, Inc.

Spy072

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

References

Drug Info

Quick Facts

Related News